A phase I study of short-course accelerated whole brain radiation therapy for multiple brain metastases

Luciana Caravatta, Francesco Deodato, Marica Ferro, Gabriella Macchia, Mariangela Massaccesi, Savino Cilla, Gilbert D A Padula, Samantha Mignogna, Rosa Tambaro, Francesco Carrozza, Mariano Flocco, Giampaolo Cantore, Andrea Scapati, Milly Buwenge, Giovanna Sticca, Vincenzo Valentini, Numa Cellini, Alessio G. Morganti

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To define the maximum tolerated dose (MTD) of a SHort-course Accelerated whole brain RadiatiON therapy (SHARON) in the treatment of patients with multiple brain metastases. Methods and Materials: A phase 1 trial in 4 dose-escalation steps was designed: 12 Gy (3 Gy per fraction), 14 Gy (3.5 Gy per fraction), 16 Gy (4 Gy per fraction), and 18 Gy (4.5 Gy per fraction). Eligibility criteria included patients with unfavorable recursive partitioning analysis (RPA) class > or Z2 with at least 3 brain metastases or metastatic disease in more than 3 organ systems, and Eastern Cooperative Oncology Group (ECOG) performance status ≤3. Treatment was delivered in 2 days with twice-daily fractionation. Patients were treated in cohorts of 6-12 to define the MTD. The dose-limiting toxicity (DLT) was defined as any acute toxicity ≥grade 3, according to the Radiation Therapy Oncology Group scale. Information on the status of the main neurologic symptoms and quality of life were recorded. Results: Characteristics of the 49 enrolled patients were as follows: male/female, 30/19; median age, 66 years (range, 23-83 years). ECOG performance status was

Original languageEnglish
JournalInternational Journal of Radiation Oncology Biology Physics
Volume84
Issue number4
DOIs
Publication statusPublished - Nov 15 2012

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase I study of short-course accelerated whole brain radiation therapy for multiple brain metastases'. Together they form a unique fingerprint.

Cite this